Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Phase 1
Suspended
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT04485052
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04466904
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, China
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04440345
- Locations
- 🇨🇳
Peking University people's hospital, Beijing, China
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Phase 1
Terminated
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT04427774
- Locations
- 🇨🇳
Jiangsu Province, Nanjing, China
Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Drug: IBI308 200mg
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04401813
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
Phase 1
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04370379
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT04353830
- Locations
- 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
Phase 1
Completed
- Conditions
- Advanced Malignant Tumors Lymphomas
- Interventions
- Biological: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT04338659
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University Of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸The University of Texas MD Anderson Cancer Center - Investigational Cancer Therapies, Houston, Texas, United States
Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors
Phase 1
Completed
- Conditions
- Advanced Malignancies
- Interventions
- Biological: IBI322
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04328831
- Locations
- 🇨🇳
Cancer hospital Chinese academy of Medical sciences, Beijing, China
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04298879
- Locations
- 🇨🇳
Ruijin hospital, school of medicine, Shanghai jiao tong university, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath